Review article: Mode of action and delivery of 5-aminosalicylic acid - New evidence

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 1, 2006, Pages 2-9

  Desreumaux, P ^a,b,c   Ghosh, S ^d  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; BALSALAZIDE; CELL NUCLEUS RECEPTOR; DIAZONIUM COMPOUND; LIGAND; MESALAZINE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; OLSALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

APOPTOSIS; CANCER RISK; CELL PROLIFERATION; COLON MUCOSA; COLORECTAL CANCER; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; HUMAN; INFLAMMATION; INTESTINE FLORA; KNOCKOUT MOUSE; LONG TERM CARE; METABOLIC REGULATION; NONHUMAN; PH; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; RISK REDUCTION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ACETYLATION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLON; DELAYED-ACTION PREPARATIONS; HUMANS; MESALAMINE; MICE; PATIENT COMPLIANCE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SULFASALAZINE;

EID: 33747620510     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03069.x     Document Type: Review

References (41)

1. Svartz N. Ett nytt sulfonamidpreparat? Forelopande meddelande [Swedish]. Nord Med 1941; 9: 554-5.
2. Baron JH, Connell AM, Lennard-Jones JE, Jones FA. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962; 1: 1094-6.
3. Misiewicz JJ, Lennard-Jones J, Conell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; i: 185-8.
4. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892-5.
5. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 410-4.
6. Vree TB, Dammers E, Exler PS, Sorgel F, Bondesen S, Maes RA. Liver and gut mucosa acetylation of mesalazine in healthy volunteers. Int J Clin Pharmacol Ther 2000; 38: 514-22.
7. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57: 267-79.
8. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1- stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274: 26448-53.
9. Dallegri F, Ottonello J, Ballestrero A, Bogliolo F, Fernando F, Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut 1990; 31: 184-6.
10. Sandoval M, Liu X, Mannick EE, Clark DA, Miller MJ. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology 1997; 113: 1480-8.
11. Burress GC, Musch MW, Jurivich DA, Welk J, Chang EB. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology 1997; 113: 1474-9.
12. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837-44.
13. Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81: 444-9.
14. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999; 116: 602-9.
15. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75: 638-40.
16. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002; 99: 13771-6.
17. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003; 124: 361-7.
18. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002; 43: 177-86.
19. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002; 360: 1410-8.
20. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001; 193: 827-38.
21. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124: 1265-76.
22. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14.
23. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005; 201: 1205-15.
24. Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996; 137: 4189-95.
25. Han J, Hajjar DP, Zhou X, Gotto AM Jr, Nicholson AC. Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem 2002; 277: 23582-6.
26. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
27. Misra P, Owuor ED, Li W, et al. Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). Stimulation of transcriptional regulation by mitogen-activated protein kinase. J Biol Chem 2002; 277: 48745-54.
28. Rocchi S, Picard F, Vamecq J, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8: 737-47.
29. Shibuya A, Wada K, Nakajima A, et al. Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett 2002; 525: 43-47.
30. Westin S, Kurokawa R, Nolte RT, et al. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 1998; 395: 199-202.
31. Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 1999; 13: 1413-7.
32. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 24-30.
33. Tsianos EV. Risk of cancer in inflammatory bowel disease (IBD). Eur J Intern Med 2000; 11: 75-78.
34. Olivier R, Rousseaux C, Lefebvre B, et al. The 5-aminosalicylic acid (5-ASA) anti-neoplasic effect in the intestine is mediated by PPARγ. Gastroenterology 2005; 128: S1386.
35. Lu D, Cottam HB, Corr M, Carson DA. Repression of beta-catenin function in malignant cells by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci USA 2005; 102: 18567-71.
36. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-8.
37. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9: 29-42.
38. Liang E, Proudfoot J, Yazdanian M. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res 2000; 17: 1168-74.
39. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology 1988; 95: 975-81.
40. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8.
41. Wallace JL. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease. Dig Liver Dis 2003; 35 (Suppl. 2): S35-40.